Immunovant Inc logo

Immunovant Inc

$ 5.58 +0.2 (+3.72%) 10:08 PM EST
P/E:
At Loss
P/B:
1.49
Market Cap:
$ 650.50M
Enterprise V:
$ 225.38M
Volume:
1.61M
Avg Vol (2M):
611.27K
Volume:
1.61M
Market Cap $:
650.50M
PE Ratio:
At Loss
Avg Vol (2-Month):
611.27K
Enterprise Value $:
225.38M
PB Ratio:
1.49
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes IMVT-1401 targets the neonatal Fc receptor (FcRn).
Name Current Vs Industry Vs History
Cash-To-Debt 204.99
Equity-to-Asset 0.95
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Book Growth Rate 1163.4
Name Current Vs Industry Vs History
5-Day RSI 76.36
9-Day RSI 65.45
14-Day RSI 59.8
6-1 Month Momentum % -6.53
12-1 Month Momentum % -40.74

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 21.48
Quick Ratio 21.48
Cash Ratio 20.11

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -100.9

Financials (Next Earnings Date:2022-11-04 Est.)

IMVT's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:IMVT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -1.47
Beta 0.9
Volatility % 46.06
14-Day RSI 59.8
14-Day ATR ($) 0.498139
20-Day SMA ($) 5.0095
12-1 Month Momentum % -40.74
52-Week Range ($) 3.145 - 9.535
Shares Outstanding (Mil) 116.58

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Immunovant Inc Filings

Document Form Filing Date
No Filing Data

Immunovant Inc Analysis

Share your research

Headlines

See More
No news.